Transition Bio
Transition Bio specializes in condensate drug discovery, leveraging advanced technology from Harvard and Cambridge labs to develop therapeutics targeting intractable molecular targets.
Company Overview
Transition Bio focuses on condensate drug discovery at the molecular level. The company advances therapeutics to address intractable targets through well-defined condensates. This approach allows for targeting specific therapeutic hypotheses with high precision.
Technology and Intellectual Property
Transition Bio's technology and intellectual property stem from the Weitz Lab at Harvard University and the Knowles Lab at the University of Cambridge. The company's platform provides the molecular lens needed to capitalize on the promise of condensate biology. This technology is integral to their approach, allowing for the identification and selection of novel binding mechanisms of action.
Drug Discovery Platform
Transition Bio utilizes a microfluidics-driven drug discovery platform, integrating droplet microfluidics and machine learning. The company employs PhaseScan™, a high throughput molecular screen, and CelPhase™, a high-content cellular imaging technique. These technologies enable precise visualization of condensates in disease cell models and patient samples. The proprietary DeePhase™ ML/AI engine supports all the company's drug discovery activities.
Funding and Locations
Transition Bio secured a $50 million Series A financing to accelerate its biomolecular condensate drug discovery efforts. The company operates from locations in Watertown, MA, USA, and Cambridge, UK.
Targeted Biology
Transition Bio focuses on well-understood and clearly defined condensate systems, including oncogenic signaling hubs, transcriptional assemblies, and RNA foci. The goal is to dissolve condensates to release sequestered biomolecules, potentially restoring a healthy state. This differentiated molecular platform aims to address previously intractable targets through advanced drug discovery methods.